Mustang Bio (MBIO) Non-Current Debt (2016 - 2023)
Mustang Bio (MBIO) posted quarterly Non-Current Debt of $27.6 million for Q1 2023, up 2.2% year-over-year from $27.0 million in Q1 2022, and up 0.52% quarter-over-quarter from $27.4 million in Q4 2022.
Mustang Bio (MBIO) Non-Current Debt (2016 - 2023) Analysis & Trends
Mustang Bio (MBIO) has reported Non-Current Debt for 5 consecutive years, with $27.6 million the latest figure, recorded in Q1 2023.
- In Q1 2023, Non-Current Debt rose 2.2% year-over-year to $27.6 million; the TTM figure through Mar 2023 stood at $27.6 million (up 2.2% YoY), while the FY2022 annual figure was $27.4 million, changed N/A from the prior year.
- Non-Current Debt rose to $27.6 million in Q1 2023 per MBIO's latest filing, from $27.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $27.6 million in Q1 2023 and bottomed at $9.0 million in Q2 2020.
- Historically, Non-Current Debt has averaged $18.8 million across 4 years, with a median of $13.2 million in 2019.
- Annual changes were most pronounced in 2020 — Non-Current Debt sank 30.82% — and 2023, when it climbed 2.2%.
- Mustang Bio's Non-Current Debt stood at $12.2 million in 2019, then retreated by 26.44% to $9.0 million in 2020, then soared by 206.24% to $27.4 million in 2022, then climbed by 0.52% to $27.6 million in 2023.
- Business Quant data shows MBIO's Non-Current Debt at $27.6 million in Q1 2023, $27.4 million in Q4 2022, and $27.3 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 8.96 Bn |
| 10 | Mustang Bio | 3.86 Mn | 3.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 27.58 Mn |
| Dec 31, 2022 | 27.44 Mn |
| Sep 30, 2022 | 27.29 Mn |
| Jun 30, 2022 | 27.15 Mn |
| Mar 31, 2022 | 26.99 Mn |
| Jun 30, 2020 | 8.96 Mn |
| Mar 31, 2020 | 10.56 Mn |
| Dec 31, 2019 | 12.18 Mn |
| Sep 30, 2019 | 13.19 Mn |
| Jun 30, 2019 | 12.95 Mn |
| Mar 31, 2019 | 12.73 Mn |
| Sep 30, 2016 | 2.93 Mn |